A detailed history of Graham Capital Management, L.P. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 34,195 shares of CPRX stock, worth $734,508. This represents 0.02% of its overall portfolio holdings.

Number of Shares
34,195
Previous 17,509 95.3%
Holding current value
$734,508
Previous $271,000 150.55%
% of portfolio
0.02%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.19 - $21.35 $253,460 - $356,246
16,686 Added 95.3%
34,195 $679,000
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $257,032 - $296,252
17,509 New
17,509 $271,000
Q3 2023

Nov 22, 2023

BUY
$11.69 - $15.02 $282,582 - $363,078
24,173 New
24,173 $282,000
Q2 2022

Aug 15, 2022

SELL
$6.23 - $8.57 $151,737 - $208,730
-24,356 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.31 - $8.31 $129,330 - $202,398
24,356 New
24,356 $201,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.21B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.